Document is current

Article History

Received: 28 January 2025

Accepted: 5 June 2025

First Online: 28 July 2025

Declarations

:

: R.P. reports grants or contracts to his institution from Gilead Sciences, Inc., M.S.D., and ViiV Healthcare; participation on advisory boards for and consulting fees from Gilead Sciences, Inc., Merck, ViiV Healthcare, Pfizer, Atea, Roche, Eli Lilly, G.S.K., and AstraZeneca; and payment or honoraria for lectures/speaker bureaus from Gilead Sciences, Inc., G.S.K., AstraZeneca, and Pfizer. R.L.G. reports grants or contracts to his institution from Eli Lilly, Gilead Sciences, Inc., Johnson & Johnson, Pfizer, and Roivant Sciences (Kinevant Sciences); participation on advisory boards for and consulting fees from AbbVie, Eli Lilly, Gilead Sciences, Inc., G.S.K., and Roche; participation on an advisory board for AstraZeneca; payment or honoraria for lectures from Gilead Sciences, Inc. and a speaker bureau from Pfizer (the latter unrelated to infectious diseases); travel support from Gilead Sciences, Inc.; de minimis stockholder at AbCellera; and a gift-in-kind to his institution from Gilead Sciences, Inc. to facilitate an unrelated academic-sponsored clinical trial (ClinicalTrials.gov Identifier: NCT03383419). L.M. reports receiving grants from Grifols; receiving honoraria as a speaker from AstraZeneca, Gilead Sciences, Inc., G.S.K., Shionogi, and Pfizer; and participation in advisory boards for Gilead Sciences, Inc. and Merck. J.D.G. reports contracted research from Gilead Sciences, Inc. and Helix; grants from Gilead Sciences, Inc.; and serving as a speaker or advisory board member for Gilead Sciences, Inc., Merck, and Invivyd. A.M.K., J.P., R.S., and R.T. were employees of Aetion, Inc., at the time of the study. M.B., E.M., R.G., M.A., and A.P.C. were employees and stockholders of Gilead Sciences, Inc., at the time of the study.